SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotime-Nasdaq's best kept secret?
BTIM 0.00010000.0%Oct 31 9:30 AM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: CMon who wrote (1425)2/1/2000 2:57:00 AM
From: E. A. Kline  Read Replies (1) of 1432
 
I've talked to some doctors and hospital administrators who've told me Hextend will never generate any significant sales b/c it's dramatically more expensive than Hespan and the other commodity products currently in use, but offers no therapeutic advantages.

Hextend's revenue is paid to BTX based on a royalty, or licensing agreement, with ABT, and so any revenue, or lack thereof, takes a quarter or two to show up. So this could be a long, slow process.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News